BlackRock Inc. Makes New $211.34 Million Investment in Inspire Medical Systems, Inc. $INSP

Key Points

• BlackRock acquired a new 16.39% stake in Inspire Medical Systems during the second quarter, purchasing 4.74 million shares valued at approximately $211.3 million. Institutional investors and hedge funds collectively own 94.91% of the company.
• Analyst sentiment remains mixed, with the stock carrying a consensus “Hold” rating and an average price target of $66.19. Oppenheimer upgraded the shares to “Outperform” with an $85 target, while other firms maintained neutral or sector-weight ratings.
• Inspire reported quarterly EPS of $0.14, beating estimates for a $0.24 loss, and revenue of $200.6 million versus expectations of $194.7 million; however, revenue declined 7.6% year over year. Shares opened at $60.84, well below their 52-week high of $147.03.

BlackRock Inc. bought a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 4,737,519 shares of the company's stock, valued at approximately $211,341,000. BlackRock Inc. owned 16.39% of Inspire Medical Systems as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. CWM LLC grew its stake in Inspire Medical Systems by 216.1% during the fourth quarter. CWM LLC now owns 354 shares of the company's stock worth $33,000 after buying an additional 242 shares in the last quarter. Havemeyer Place LP bought a new position in Inspire Medical Systems in the 4th quarter valued at about $39,000. Smartleaf Asset Management LLC raised its position in shares of Inspire Medical Systems by 84.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock valued at $42,000 after buying an additional 205 shares in the last quarter. Daiwa Securities Group Inc. raised its position in shares of Inspire Medical Systems by 38.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company's stock valued at $60,000 after buying an additional 130 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Inspire Medical Systems by 1,115.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company's stock worth $33,000 after acquiring an additional 580 shares during the period. 94.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. KeyCorp reiterated a "sector weight" rating on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Royal Bank Of Canada restated a "sector perform" rating and set a $60.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Oppenheimer upgraded Inspire Medical Systems from a "market perform" rating to an "outperform" rating and set a $85.00 target price for the company in a research note on Tuesday, August 4th. Robert W. Baird raised their target price on Inspire Medical Systems from $54.00 to $59.00 and gave the company a "neutral" rating in a report on Tuesday, August 4th. Finally, Wells Fargo & Company decreased their price target on Inspire Medical Systems from $70.00 to $56.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $66.19.

Inspire Medical Systems Stock Performance

Shares of INSP opened at $60.84 on Friday. Inspire Medical Systems, Inc. has a 52 week low of $38.91 and a 52 week high of $147.03. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of 13.17, a PEG ratio of 4.70 and a beta of 0.70. The stock has a fifty day moving average of $52.73 and a 200-day moving average of $52.44.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.38. The firm had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The business's quarterly revenue was down 7.6% on a year-over-year basis. During the same period last year, the company earned $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities analysts forecast that Inspire Medical Systems, Inc. will post 1.24 EPS for the current year.

Insider Transactions at Inspire Medical Systems

In other news, insider Jason P. Kelly sold 963 shares of Inspire Medical Systems stock in a transaction on Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. The trade was a 4.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.20% of the stock is currently owned by company insiders.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.